February 25, 2020

Dear Valued Former Employee,

Mallinckrodt plc today announced an important step forward that removes significant uncertainty related to our business and better enables us to move ahead with our strategic plans.

We reached an agreement in principle on the terms of a global settlement that would provide a comprehensive resolution to all opioid-related claims against Mallinckrodt, Specialty Generics, and the Company’s other subsidiaries. The agreement is with a court-appointed plaintiffs’ executive committee representing the interests of thousands of plaintiffs in the opioid multidistrict litigation\(^1\), and is supported by a broad-based group of 47 state and U.S. Territory Attorneys General.

To implement the proposed settlement, we expect that Specialty Generics will file for Chapter 11 in the coming months. Our Specialty Brands business will not be part of the contemplated Chapter 11 filing.

This court-supervised process is expected to lead to the creation of a trust which, among other things, would establish an abatement fund to offset the expense of helping to combat opioid addiction and providing support to communities impacted by opioid abuse. This process would also provide a fair, orderly, efficient and legally binding mechanism to resolve all opioid-related claims.

No Impact on You

As we move forward, please keep in mind:

- The contemplated Chapter 11 filing by the Specialty Generics business would have no impact on Mallinckrodt retirees or former employees, regardless of which business you worked for or supported;
- If you are receiving a pension, your pension benefits have either been paid as a lump sum or received in a guaranteed annuity contract;
- If you were or are a participant in the Mallinckrodt Pharmaceuticals Supplemental Savings and Retirement Plan (SSRP), you will continue to receive payments in accordance with your elections; the SSRP is not part of the entity that is contemplating Chapter 11; and
- Other post-employment benefits are also fully expected to continue as normal.

Additional Information

We have created a website with information specific to the proposed settlement, which you can visit at www.advancingmnk.com.

Thank you for your service to Mallinckrodt and the patients we serve.

Sincerely,

Spiro Gavaris
President, Mallinckrodt Specialty Generics

\(^1\)Captioned In re National Prescription Opiate Litigation, Case No. 17-md-2804 (N.D. Ohio).